Efficacy and safety of the combination of encorafenib and cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: An AGEO real-world multicentre study

被引：2

作者：

Gallois, C. ^{[1
]}

Elez Fernandez, M. E. ^{[2
]}

Auclin, E. ^{[3
]}

Bergen, E. S. ^{[4
]}

Pernot, S. ^{[5
]}

Higue, J. ^{[6
]}

Trouilloud, I. ^{[7
]}

Touchefeu, Y. ^{[8
]}

Turpin, A. ^{[9
]}

Mazard, T. ^{[10
]}

Pilla, L. ^{[1
]}

Cuissy, S. ^{[11
]}

Wookey, V. ^{[12
]}

Perret, A. ^{[13
]}

Melchior, C. ^{[14
]}

Artru, P. ^{[15
]}

Stintzing, S. ^{[16
]}

Dubreuil, O. ^{[17
]}

Tougeron, D. ^{[18
]}

Taieb, J. ^{[19
]}

机构：

[1] Hop Europeen Georges Pompidou, AP HP, Digest Oncol Dept, Paris, France

[2] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

[3] Hop Europeen Georges Pompidou, AP HP, Oncol Dept, Paris, France

[4] Univ Kliniken MedUni Wien AKH Wien, Div Oncol, Dept Med 1, Vienna, Austria

[5] Inst Bergonie, Digest Med Oncol Unit, Bordeaux, France

[6] Inst Univ Canc Toulouse Oncopole, Haute Garonne, Toulouse, France

[7] Hop St Antoine, Med Oncol Dept, Paris, France

[8] CHU Nantes, Digest Oncol, Hotel Dieu, Nantes, France

[9] CHU Lille, Dept Med Oncol, Lille, France

[10] Inst Canc Montpellier, Med Oncol, Montpellier, France

[11] CHU Rouen Normandie, Seine Maritime, Rouen, France

[12] Mayo Clin, Dept Oncol, Rochester, MN USA

[13] Inst Gustave Roussy, Digest Oncol Dept, Villejuif, France

[14] Ctr Leon Berard, Digest Oncol Dept, Lyon, France

[15] Hop Prive Jean Mermoz, GI Oncol Dept, Lyon, France

[16] Charite Univ Med Berlin, Hematol Oncol & Canc Immunol CCM Dept, Berlin, Germany

[17] Gh Diaconesses Croix St Simon, Med Oncol, Paris, France

[18] CHU Poitiers, Dept Gastroenterol & Hepatol, Jean Bernard Hop, Poitiers, France

[19] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1816

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

625P

引用

页码：S446 / S446

页数：1

共 50 条

[1] Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
Gallois, C.
Bergen, E. S.
Auclin, E.
Pernot, S.
Higue, J.
Trouilloud, I.
Touchefeu, Y.
Turpin, A.
Mazard, T.
Sartore-Bianchi, A.
Prenen, H.
Alberti, A.
Pilla, L.
Cuissy, S.
Wookey, V.
Perret, A.
Melchior, C.
Artru, P.
Dubreuil, O.
Drouillard, A.
Doat, S.
Lavole, J.
Basile, D.
Perkins, G.
Jary, M.
Stintzing, S.
Jos, J.
Tougeron, D.
Taieb, J.
ESMO OPEN, 2024, 9 (09)
[2] Safety of encorafenib, binimetinib, plus cetuximab for Japanese patients with BRAF V600E metastatic colorectal cancer
Yamaguchi, Toshifumi
Daisuke, Kotani
Atsuo, Takashima
Takeshi, Kato
Toshiki, Masuishi
Yoshito, Komatsu
Manabu, Shiozawa
Taito, Esaki
Naoki, Izawa
Shinji, Takeuchi
Hideaki, Bando
Satoru, Iwasa
Hiroko, Hasegawa
Taroh, Satoh
Hiroya, Taniguchi
Takayuki, Yoshino
ANNALS OF ONCOLOGY, 2022, 33 : S479 - S479
[3] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
Martina Eriksen
Per Pfeiffer
Kristoffer Staal Rohrberg
Christina Westmose Yde
Lone Nørgård Petersen
Laurids Østergaard Poulsen
Camilla Qvortrup
BMC Cancer, 22
[4] A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study
Eriksen, Martina
Pfeiffer, Per
Rohrberg, Kristoffer Staal
Yde, Christina Westmose
Petersen, Lone Norgard
Poulsen, Laurids Ostergaard
Qvortrup, Camilla
BMC CANCER, 2022, 22 (01)
[5] Encorafenib, binimetinib, and cetuximab combination therapy for patients with BRAF V600E mutant colorectal cancer
Moro, Kazuki
Saiki, Takuro
Sasaki, Kenta
Matsumoto, Akio
Zhou, Qiliang
Nakano, Mae
Nakano, Masato
Matsumoto, Yoshifumi
Shimada, Yoshifumi
Moriyama, Masato
Wakai, Toshifumi
Saijo, Yasuo
ANNALS OF ONCOLOGY, 2022, 33 : S541 - S541
[6] Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC
von der Heyde, E.
Buerkle, D.
Forstbauer, H.
Huebner, G.
Schmidt, B.
Schroeder, J.
Distelrath, A.
Wierecky, J.
Stuebs, P.
Kisro, J.
Welslau, M.
Mueller-Huesmann, H.
Goehler, T.
Krammer-Steiner, B.
Schwaner, I.
Hering-Schubert, C.
Gerger, A.
Greil, R.
Jacobasch, L.
Reichenbach, F.
Stintzing, S.
Prager, G.
ANNALS OF ONCOLOGY, 2022, 33 : S248 - S248
[7] Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
Ros, Javierd
Saoudi, Nadia
Baraibar, Iosune
Salva, Francesc
Tabernero, Josep
Elez, Elena
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
[8] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Prasad, Vinay
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 876 - 876
[9] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Roviello, Giandomenico
D'Angelo, Alberto
Petrioli, Roberto
Roviello, Franco
Cianchi, Fabio
Nobili, Stefania
Mini, Enrico
Lavacchi, Daniele
TRANSLATIONAL ONCOLOGY, 2020, 13 (09):
[10] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Kopetz, S.
Grothey, A.
Yaeger, R.
Van Cutsem, E.
Desai, J.
Yoshino, T.
Wasan, H.
Ciardiello, F.
Loupakis, F.
Hong, Y. S.
Steeghs, N.
Guren, T. K.
Arkenau, H. -T.
Garcia-Alfonso, P.
Pfeiffer, P.
Orlov, S.
Lonardi, S.
Elez, E.
Kim, T. -W.
Schellens, J. H. M.
Guo, C.
Krishnan, A.
Dekervel, J.
Morris, V.
Calvo Ferrandiz, A.
Tarpgaard, L. S.
Braun, M.
Gollerkeri, A.
Keir, C.
Maharry, K.
Pickard, M.
Christy-Bittel, J.
Anderson, L.
Sandor, V.
Tabernero, J.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (17): : 1632 - 1643

← 1 2 3 4 5 →